Biophytis Announces An Exclusive License Agreement With Blanver For BIO101 (20-hydroxyecdysone) In Latin American, Biophytis Will Be Able To Receive Up To €108M Including An Upfront Payment And Further Additional Milestone Payments
Biophytis Announces An Exclusive License Agreement With Blanver For BIO101 (20-hydroxyecdysone) In Latin American, Biophytis Will Be Able To Receive Up To €108M Including An Upfront Payment And Further Additional Milestone Payments
The agreement provides that Blanver will be responsible for the registration, marketing and commercialization of BIO 101 (20-Hydroxyecdysone) in its various indications: obesity, respiratory infections due to Covid-19, sarcopenia and Duchenne Muscular Dystrophy (DMD) - once Biophytis has successfully completed the planned clinical development programmes for its drug candidate. With 40 years of history, Blanver has become an expert in infectious diseases, osteoporosis and metabolic disorders, which is a perfect match with Biophytis. In addition of Brazil, Blanver has an extensive network of unique distributors that covers the whole Latin America region.
協議規定，一旦Biophytis成功完成其藥物候選的計劃臨床開發項目，Blanver將負責BIO 101（20-Hydroxyecdysone）在其各種適應症（包括肥胖症，由Covid-19引起的呼吸系統感染，肌無力症和杜興肌肉萎縮症）的註冊，營銷和商業化。擁有40年曆史的Blanver已成爲傳染病，骨質疏鬆症和代謝性疾病的專家，這與Biophytis非常相配。除了巴西，Blanver還擁有一個廣泛的獨特分銷網絡，覆蓋整個拉丁美洲地域板塊。